Fast Company selects biotech companies as part of its list of innovative companies for 2019

For its 2019 list of top 50 most innovative companies, Fast Company selected 10 of the biotechnology industry that have a significant impact on the treatment of patients. The top five are highlighted below.

Basic medicine – In June 2018, the Foundation Medicine Sequencing Diagnostics Company is awarded under the patronage of the Swiss pharmaceutical giant rock in one $ 2.4 billion contract. Despite its acquisition, Foundation Medicine remains an independent company of Roche. It has been selected for the Fast Company Ranking for its innovative sequencing platform, which includes its approved F1CDx test, which evaluates all classes of genomic alterations in 324 genes known to stimulate cancer growth. In September, the company was awarded the Breakthrough Devices label for its extensive "liquid biopsy" test that analyzes blood for 70 genes related to cancer growth, allowing physicians to monitor treatment response without taking invasive tissue samples , explained Fast Company.

arteries – Arterys, based in San Francisco, has been selected for its use of artificial intelligence in support of clinical trials. In 2017, the US Food and Drug Administration approved the application Arterys Cardio DL. Arterys technology is the first of its kind to receive US accreditation that leverages cloud computing and deep learning in a clinical environment. The Arterys system provides automated and modifiable ventricular segmentation based on conventional cardiac MRI images as accurate as manual segmentation by experienced physicians, according to the company.

Alnylam – Alnylam, based in Massachusetts, was placed on the list for being the first company to market RNAi-based therapy. The company won FDA approval in August 2018 for Onpattro (Patisiran). The drug is used for the treatment of transthyretin-mediated hereditary amyloidosis (HATTR) polyneuropathy in adults. HATTR amyloidosis is a rare disease that affects around 50,000 people worldwide. Recent studies suggest that RNAi-based drugs could also target neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and ALS, Fast Company said.

Flatiron Health – Also snapped up by Roche in 2018, Flatiron Health has developed its Health OncologyCloud platform, which includes state-of-the-art electronic medical records, advanced analytics, patient portal and integrated billing management. Its technology is an aggregation data resource that allows researchers to develop an understanding of the real world in the ever-changing landscape of oncology. Flatiron was founded by former Google employees. Nat Turner and Zach Weinberg. In announcing the agreement with Roche, Flatiron announced that it would pursue its current business model, which includes a network of partnerships including partnerships with Celgene and Amgen.

Amgen – Talking about Amgen, the Californian company came fifth on Fast Company's list of innovative biotechnologies. While Amgen is one of the world's largest biotech companies with a number of successful treatments, such as Enbrel, Fast Company has singled out one of its most successful treatments. recently approved by the FDA, Aimovig. The drug was co-developed by Amgen and the Swiss pharmaceutical giant Novartis. Aimovig has been approved for the preventive treatment of migraine in adults. The migraine medication has been approved on the basis of superb phase III data this showed Aimovig halved monthly migraine attacks. Aimovig was the first of a new class of anti-CGRP drugs to be approved for the treatment of migraine headaches. Discover the jobs available at Amgen!

Viz.ai, Velano Vascular, Berkley Lights, T2 Biosystems and Catalog are among the other five biotech companies that have been featured in Fast Company's Top 10 list.